Abstract
This paper summarises the results of an investigation of willingness to pay (WTP) for new vaccines. The vaccines considered are for infections with several subtypes. One option is to cover a broad combination of these within one vaccine although this is associated with additional development complexities. The associated durations of effect of such vaccines are not yet known; therefore the impact of variations in this and the subtype coverage, as well as that of opting for a non-reimbursement status, were among the issues that needed to be assessed. One important group for a determination of WTP is parents, in that they could be paying for vaccination of themselves and/or their children. This paper reports the findings of WTP among this group for their children for alternative outcomes in the vaccine product profile. For reasons of confidentiality, results from only this group in the context of paying for their children are reported. The exact wording of the product features tested have also been changed for the same reason.
Get full access to this article
View all access options for this article.